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Summary
A major 18-kD IgE-binding protein from Aspergillusfumigates (AspfI) has been purified . Partial
amino acid sequencing of Aspf I showed extensive sequence homology (95%) between Asp
fI and a cytotoxin (mitogillin) produced byA . restrictus. Crossinhibition radioimmunoassay using
murine monoclonal antibody andhumanIgG and IgE antibodies showed that AspfI and mito
were antigenically indistinguishable. Furthermore, both proteins inhibited protein synthesis in
vitro by >90% . AspfI was expressed in A . fumigates but not in seven other Aspergillus species .
The results suggest that AspfI could play a dual role in the pathogenesis ofA . fumigates-related
diseases by promoting colonization through cytotoxic activity and by causing inflammatory reactions
involving IgE antibodies .
Aspergillusfumigates causes a diverse spectrum of human
diseases, including allergic bronchopulmonary aspergil-
losis (ABPA), asthma, aspergilloma, and invasive infection
in immunocompromised hosts (1) . The respiratory tract of
patients with chronic pulmonary diseases, particularly cystic
fibrosis (2, 3), is frequently colonized byA .fumigates . How-
ever, despite the ability of the fungus to cause tissue inva-
sion, respiratory colonization byA . fumigates is often regarded
as saprophytic or benign . Serologic studies have shown that
colonization can induce IgG and/or IgE antibodies to several
A . fumigatus antigens (4-7), however, the structure and func-
tion of these antigens are largely unknown . In this report,
we describe the purification of an 18-kD IgE-binding pro-
tein from A . fumigatus (Aspf I) that is selectively expressed
inA . fumigatus . Structural, functional, and antigenic anal-
yses show that Aspf I is a member of the mitogillin family
of cytotoxins (8, 9) .
Materials and Methods
Purification ofAspfI .
￿
A. fumigates culture (30 g, strain no.
5167; Greer Laboratories, Lenoir, NC) was extracted overnight in
300 ml borate-buffered saline, pH 8.0 (BBS), and centrifuged
(20,200 g, 30 min) .A. fumigatus antigens were partially purified
from the supernate by gel filtration and phenyl-Sepharose chroma-
tography. A panel of six murine IgG1 mAbs was raised against
an N20-kD, 2M N2CI phenyl-sepharose fraction . mAb 4A6 showed
the highest binding to the I'll 2 M fraction in RIA and recog-
nized an 18-kD protein. This protein, AspfI, was purified byaffinity
chromatography over mAb 4A6 immunosorbent followed by size
exclusion HPLC using a Sepharose 12 HR 10/30 column (Phar-
macia Fine Chemicals, Piscataway, NJ) . The yield was Wing Asp
f I . Purity was assessed by SDS-PAGE using an 8-25% gel on a
PhastSystem (Pharmacia Fine Chemicals) .
AminoAridSequencing.
￿
100pgAspfIwas reduced and alkylated
using 0.5% (vol/vol) 2-ME and 4% (vol/vol) vinyl pyridine and
injected onto a reverse-phase HPLC column (C8 ; Brownlee Labs,
Santa Clara, CA) . The NH2-terminal amino acid sequence (27
residues) of the HPLC peak was determined using a gas phase se-
quencer (477-A; Applied Biosystems, Inc ., Foster City, CA) . Four
tryptic peptides (Ts, residues 22-28 ; Tz , 29-38; T3, 43-60; and
T4, 121-128) were sequenced as single sharp peaks from a reverse-
phaseHPLC column (C18 ; Applied Biosystems, Inc.) ACNBr frag-
ment was also sequenced (residues 87-107) .
IgEAntibody Assays.
￿
mAb 4A6 was used in a solid-phase RIA
to present AspfI to IgE antibodies. Bound IgE antibodies were
detected by the addition of2 ng affinity-purified, ' 211-labeled goat
anti-human IgE . Specific IgE antibody to AspfI or to mitogillin
was also determined by double antibody antigen-bindingRIA (10) .
IgE antibody to A.fumigates was measured by quantitative radio-
allergosorbent test (RAST) (11) .
CrossinhibitionRIA .
￿
Serial fourfold or 10-fold dilutions ofcold
AspfI or mitogillin were incubated for 2 h with 60 ngmAb 4A6
or with 0 .1 ml 1/4 or 1/25 dilution of serum from a patient with
ABPA (l.H .) for the IgE and IgG assays, respectively. Subsequently,
6 ng of 121 1 AspfI or 4 ng'uI mitogillin was added for 2 h, and
antigen-antibody compleates were precipitated overnight using mono-
specific goat or sheep antisera (10) . Precipitates were washed with
BBS and counted in a gamma counter.
Inhibition ofProtein Synthesis.
￿
AspfI and mitogillin were used
to inhibit protein synthesis in a rabbit reticulocyte lysate in vitro
translation system for Brome Mosaic Virus (Promega Biotec,
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in 7 gl RNAase free distilled water. Total "S-methionine incor-
poration (TCA precipitable counts) was determinedby adding 7 ttl
distilled water only, and a reaction mixture containing no BMV
mRNA was used to determine background counts .
Human Sera and Skin Testing.
￿
Sera were obtained from six
nonallergic control subjects and from 46 patients who had either
positive immediate skin tests or serum IgE antibodies toA .fumigates
and clinical symptoms of ABPA (n = 14), cystic fibrosis and
ABPA (n = 21), or asthma (n = 11) . Intradermal skin tests were
carried out using' serial 10-fold dilutions of Asp f I, from 10-
10-6 I~g/ml (10) .
Results and Discussion
We initially raised a mAb (clone 4A6) against partially
purifiedA . fumigates antigen and found that it recognized
a single18AD band on immunoprecipitation . ThemAb was
used in a solid-phase RIA to present the antigen to human
IgE antibodies. Of 13 patients with ABPA or asthma and
positive serum IgE antibodies toA .fumigates(RAST > 200
U/ml), 11 (85%) had IgE antibodies to the 18-kD antigen .
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￿
SDS-PAGE and amino acid sequence comparisons of Aspf 1
(18 kD) and mitogillin (16 .2 kD) . (A) Silver-stained SDS-PAGE analysis
ofA . fumigates extract (lanes 1-3), 2 M phenyl-sepharose fraction (lanes
4 and 5), mitogillin (lane 6), and Asp f I (lane 7). Aspf I shows a high
molecularweight band similar to that observed in mitogillin preparations
and previously interpreted as a dimer (9) . (B) Amino acid sequence ho-
mology between AspfI and mitogillin: 77/81 (95%) residues of AspfI
were identical to the published mitogillin sequence (8) . Aspf I residues
that differ frommitogillin are indicated (* ) . Mitogillin was kindly provided
by Dr. Ted Watson (MichiganDepartment ofPublic Health, Lansing, MI) .
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Patients with equivocal or weakly positiveA .fumigates RAST
(n = 10 ; geometric mean, 29.5 U/ml) had no detectable IgE
antibody. These results showed that the 18-kD antigen defined
by mAb 4A6 was an important allergen . The allergen was
purified by affinity chromatography and size exclusionHPLC
(Fig. 1 A) and has provisionally been designatedAspfI. Par-
tial amino acid sequencing of AspfI showed extensive se-
quence homology (95%) between Aspf I and mitogillin, a
cytotoxin produced byA . restrictus (Fig. 1 B) . Mitogillin is
a member of a family of cytotoxins that includes a-sarcin
and restrictocin, produced by A . giganteus andA . restrictus,
respectively. These cytotoxins are potent inhibitors of pro-
tein synthesis and act by cleaving the 3' end of the largeRNA
from the 60S ribosomal subunit (9) . Mitogillin also causes
regression of murine and canine tumors in vivo (12) . Linear
regression analysis showed an excellent quantitative correla-
tion between IgE antibodies toAspfIand to mitogillin (Fig.
2) . On immediate skin testing, four offive patients with posi-
tive prick tests toA .fumigates gave positive intradermal skin
tests (> 6 x 6-mm wheal) to Aspf I at 10-2-10-6 Ug/ml) .
In contrast, two patients with positive skin tests to other
allergens, but not to A . fumigates, and four nonatopic con-
trols, gave negative skin tests to 10 ug/ml Asp f I.
We investigated the antigenic and functional relationships
between AspfI and mitogillin by crossinhibition RIA and
by inhibition of cell-free protein synthesis in vitro . Superim-
posable, dose-dependent inhibition curves were obtained using
cold Aspf I or mitogillin to inhibit the binding of either
1251-labeled proteins to mAb 4A6 or to human IgG or IgE
antibody (Fig . 3) . This effect was species specific in that ex-
tracts of seven other Aspergillus species, representative of dis-
tinct classification groups of the Aspergilli (13), caused<10%
inhibition . Together, these results showed that AspfI and
mitogillin were antigenically indistinguishable . Using rabbit
reticulocyte lysate to synthesizeBrome Mosaic Virus protein,
we observed >90% inhibition o£ protein synthesis by both
mitogillin and AspfI at concentrations of<20 ng/ml (Table
O
100 -1 n_37
r-0.96
P<0.001
1
￿
1,0
￿
100
izs1 ASP f I bound (cpm x 103)
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Figure 2 .
￿
Correlation between the binding of 1251 Asp f I or 1251
mitogillin to IgE antibodies in sera from 10 patients with ABPA (" ),
21 patients with cystic fibrosis and ABPA (A), and six control subjects
(O), determined by antigen-binding RIA .1). Inhibition ofprotein synthesisby either molecule was not
blockedby mAb 4A6, suggesting that theepitope recognized
bymAb 4A6 is notlocated near the active site for ribosomal
cleavage (Table 1) .
A. fumigatus is the most common member of the genus
Aspergillus that is associated with human disease, however,
Table 1.
￿
AspfI and Mitogillin Inhibit In Vitro Protein Synthesis
Figure 3 .
￿
Antigenic identity between Aspf
I and mitogillin . Binding of 1251 Aspf I to mu-
rine mAb 4A6 (a), humanIgE (b), and human
IgG (c), and of 12SI mitogillin to mAb 4A6 (d),
IgE (e), andIgG (f) was inhibited by cold Asp
~f
￿
f I ("), cold mitogillin (O), or by extracts of
A. niger ([I), A. nidulans (A), A . tennis (0),
A. glaucus (0),A. clavatus (0), A. sydowi (O),
orA.lavus (A) . Results are expressed as the per-
cent inhibition of 1251 AspfI or 1251 mitogillin
binding relative to themean of four 'tubes con-
taining 1% BSA-PBST (uninhibited controls) .
Using 1251 Asp f I, uninhibited binding was
37,530 cpm (mAb 4A6), 5,903 cpm (IgE), and
40,973 cpm (IgG); and uninhibitedbinding using
1251 mitogillin was 71,361 cpm (mAb 4A6),
21,045 cpm (IgE), and 67,854 cpm (IgG) . Each
point represents the mean of duplicate assays.
thereasonswhyA .fumigatus frequently colonizes the lungs
are poorly understood (14, 15) . Cytotoxic metabolites ofA .
fumigatus (e.g., gliotoxin and fumagillin) are thoughtto facili-
tate fungal growth by inhibiting macrophage function and
causing immunosuppression (15, 16). Unlike Aspf I, none
of the low molecular weight metabolites induce IgE anti-
Serial fourfold dilutions of either Aspf I or mitogillin were used to inhibit incorporation of 35S-methionine in an in vitro translation system for
BMV protein. Incorporation of 35S-methionine into protein was determined by TCA precipitation, and the results are expressed as cpm incorpor-
ated (x 103) . In addition, for each reaction tube, theTCA precipitable counts were divided by the total counts added, and the percentage inhibition
of the acid precipitable counts as compared with uninhibited controls is shown in parentheses . The estimated dose for 50% inhibition was 4 ng/ml
for AspfI and0.25 ng/ml for mitogillin . In a parallel experiment, we included the major cat allergen, Fel d I, at 20 jig/ml, as a negative control
and observed <2% inhibition of protein synthesis .
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Inhibitor
"S-Met
AspfI
incorporation (percent inhibition)
Mitogillin
cpm x 10 3
80.0 ug/ml 22.7 (96.0) 22.9 (96.3)
20.0 ng/ml 35.9 (92 .2) 30.0 (94.6)
5.0 ng/ml 236.1 (64.9) 38.4 (92.8)
1 .2 ng/ml 613.9 (-6.2) 42.9 (91.9)
0.3 ng/ml 417.3 (4.3) 175.0 (68.7)
20 Wg/ml inhibitor + 500 Fg/ml mAb 4A6 9.1 (97.7) 8.1 (98.2)
Background (no mRNA) 8 .5
Uninhibited positive control 545 .2body formation . Mitogillin(s) were not previously known
to occur in pathogenic Aspergilli, nor to cause IgE antibody
responses, although, interestingly, hypersensitivity reactions
(anaphylaxis and skin rashes) hampered US. trials of mitogillin
in cancer chemotherapy (Dr. Ted Watson, personal commu-
nication ; see also reference 12) . Our results suggest that
Asp fI could play a dual role in the pathogenesis ofA.
fumigates-related diseases by promotingfungal colonization
throughcytotoxic activity andby causing inflammatory reac-
tions involving IgE antibodies present on human lung mast
cells. Cytotoxic damage to the respiratorymucosa would be
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